Bafna Pharmaceuticals Limited (NSE:BAFNAPH)
242.45
+4.75 (2.00%)
Aug 21, 2026, 3:14 PM IST
Bafna Pharmaceuticals Revenue
Bafna Pharmaceuticals had revenue of 265.83M INR in the quarter ending June 30, 2026, a decrease of -23.22%. This brings the company's revenue in the last twelve months to 1.43B, down -3.14% year-over-year. In the fiscal year ending March 31, 2026, Bafna Pharmaceuticals had annual revenue of 1.51B with 3.26% growth.
Revenue (ttm)
1.43B
Revenue Growth
-3.14%
P/S Ratio
4.02
Revenue / Employee
3.51M
Employees
406
Market Cap
5.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.51B | 47.60M | 3.26% |
| Mar 31, 2025 | 1.46B | -66.09M | -4.33% |
| Mar 31, 2024 | 1.52B | 371.16M | 32.18% |
| Mar 31, 2023 | 1.15B | 302.10M | 35.48% |
| Mar 31, 2022 | 851.40M | 139.22M | 19.55% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 18.73B |
| Windlas Biotech | 9.42B |
| Sigachi Industries | 4.76B |
| Beta Drugs | 4.10B |
| Valiant Laboratories | 3.06B |
| Jagsonpal Pharmaceuticals | 2.94B |
| Amanta Healthcare | 2.91B |
| Sakar Healthcare | 2.72B |
Bafna Pharmaceuticals News
- 11 days ago - Bafna Pharmaceuticals Quarterly report: Q1 2027 - Filings
- 3 months ago - Bafna Pharmaceuticals Quarterly report: Q4 2026 - Filings
- 3 months ago - Bafna Pharmaceuticals Annual report: Q4 2026 - Filings
- 6 months ago - Bafna Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 10 months ago - Bafna Pharmaceuticals Quarterly report: Q2 2026 - Filings